Literature DB >> 10554325

The establishment of sublines with opposite chemosensitivity from a patient with pulmonary large cell carcinoma and the implementation of treatment based on tumor heterogeneity.

S Kobayashi1, S Okada, T Hasumi, N Sato, S Fujimura.   

Abstract

Two sublines were established from the primary tumor of a patient with pulmonary large cell carcinoma. These two sublines had different growth characteristics in vitro and different tumor tissue structure in nude mice, and opposite drug sensitivities. Subline 1 was sensitive to a number of drugs, while its sensitivity to cisplatin (CDDP) was not very strong. In contrast, subline 2 was resistant to many drugs, but showed very strong sensitivity to CDDP. When the patient developed recurrence, he was first treated with CDDP-based chemotherapy based on the sensitivity of subline 2, followed by methotrexate-based treatment on the basis of sensitivity for subline 1. Complete remission (CR) was achieved after this alternating chemotherapy. To our knowledge, this is the first report of sublines with opposite sensitivity being established from the same tumor, achieving CR by the treatment of each subline.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554325     DOI: 10.1007/s005950050639

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  15 in total

1.  The role of surgical resection and the effects of neo-adjuvant therapy in the management of small cell lung cancer.

Authors:  S Namikawa; T Den; M Kimura; M Kusagawa
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 2.  Autologous bone marrow transplantation for the treatment of lung cancer.

Authors:  H M Lazarus
Journal:  Semin Oncol       Date:  1993-10       Impact factor: 4.929

3.  Simultaneous in vitro drug sensitivity testing on tumors from different sites in the same patient.

Authors:  D D Von Hoff; G M Clark; B J Forseth; J D Cowan
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

4.  Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A Hoosier Oncology Group study.

Authors:  E Eklund; M E Miller; R Ansari; W B Fisher; L H Einhorn
Journal:  Am J Clin Oncol       Date:  1991-10       Impact factor: 2.339

Review 5.  Chemosensitivity testing in ovarian cancer.

Authors:  B U Sevin; J P Perras; H E Averette; D M Donato; M Penalver
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

6.  Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.

Authors:  P J Hesketh; S Tansan; P B Caguioa; A Hesketh; R Blanchard; N DiMartino; D Carney
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

7.  Characterization and the clinical application of cultured human pulmonary carcinoma cells.

Authors:  S Kobayashi; S Fujimura
Journal:  Tohoku J Exp Med       Date:  1992-10       Impact factor: 1.848

8.  Intratumoral heterogeneity for amplified genes in human breast carcinoma.

Authors:  U Lönn; S Lönn; B Nilsson; B Stenkvist
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

9.  Genomic alterations in sarcomas: a histologic correlative study with use of oncogene panels.

Authors:  M W Maillet; R A Robinson; L J Burgart
Journal:  Mod Pathol       Date:  1992-07       Impact factor: 7.842

10.  Heterogeneous radiation and heat sensitivity in vitro of human melanoma xenograft lines established from different lesions in the same patient. Comparisons with the radiation and heat sensitivity of cells isolated from the donor patient's surgical specimens.

Authors:  E K Rofstad; N Zaffaroni; M E Hystad
Journal:  Int J Radiat Biol       Date:  1990-06       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.